Synapse - Advanced Practice Providers

Results (105)

Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma

Journal Article

Torka, P.; Feldman, T.; Savage, K. J.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Capadona, C.; Subzwari, S.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation

Journal Article

Kumar, A.; Soumerai, J.; Abramson, J. S.; Barnes, J. A.; Caron, P.; Chhabra, S.; Chabowska, M.; Dogan, A.; Falchi, L.; Grieve, C.; more...
Blood (2025)

Fulltext@MSK | Save

Pembrolizumab for front-line treatment of extranodal NK/T-cell lymphoma

Meeting Abstract

Moskowitz, A.; Advani, R. H.; Ganesan, N.; Chang, T.; Hancock, H.; Davey, T.; Miller, T.; Gibaldi, A.; Smith, M.; Assini, A.; more...
Blood (2024)

Fulltext@MSK | Save

Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma

Meeting Abstract

Stuver, R.; Vardhana, S. A.; Ganesan, N.; Boardman, A. P.; Caron, P.; Chang, T.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
Blood (2024)

Fulltext@MSK | Save

Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: A phase 1b/2a trial

Journal Article

Horwitz, S. M.; Nirmal, A. J.; Rahman, J.; Xu, R.; Drill, E.; Galasso, N.; Ganesan, N.; Davey, T.; Hancock, H.; Perez, L.; more...
Nature Medicine (2024)

Fulltext@MSK | Save

Pilot study of longitudinal geriatric assessment and neurocognitive evaluation in CAR T-cell therapy for older patients with relapsed refractory, large B-cell lymphoma

Meeting Abstract

Lin, R. J.; Kim, S. J.; Correa, D.; Elko, T. A.; Lobaugh, S.; Baser, R.; Koch, A.; Hanley, D. M.; Palomba, M. L.; Dahi, P. B.; more...
Blood (2023)

Fulltext@MSK | Save

Reduced dose brentuximab vedotin for mycosis fungoides appears to prolong response duration by balancing efficacy and tolerability

Meeting Abstract

Munayirji, B.; Khan, N.; Myskowski, P.; Geller, S.; Noor, S.; Kheterpal, M. K.; Davey, T.; Hancock, H.; Perez, L.; Miller, T.; more...
Blood (2023)

Fulltext@MSK | Save

A multicenter phase 2 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in patients with treatment-naïve, TP53-mutant mantle cell lymphoma

Meeting Abstract

Kumar, A.; Soumerai, J.; Abramson, J. S.; Barnes, J. A.; Caron, P.; Chabowska, M.; Devlin, M.; Dogan, A.; Falchi, L.; Garcia, R. N.; more...
Blood (2023)

Fulltext@MSK | Save

A phase II trial of prophylactic anakinra to prevent neurotoxicity in patients receiving anti-CD19 CAR T-cell therapy for relapsed or refractory lymphoma: Final results from cohort 2

Meeting Abstract

Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G. L.; Dahi, P. B.; Lin, R. J.; Scordo, M.; Perales, M. A.; Leslie, L. A.; more...
Blood (2023)

Fulltext@MSK | Save

Ruxolitinib promotes clinical responses in large granular lymphocytic leukemia via suppression of JAK/STAT-dependent inflammatory cascades

Meeting Abstract

Moskowitz, A.; Rahman, J.; Ganesan, N.; Hannigan, K.; Ksanznak, K.; Bitton, H.; Lin, Y. H.; Davey, T.; Hancock, H.; Perez, L.; more...
Blood (2023)

Fulltext@MSK | Save